20.5 C
New York
Sunday, June 7, 2026

Tag: Author

University of Phoenix researchers publish study examining doctoral students’ attitudes toward AI chatbots and ChatGPT use in higher education

Peer-reviewed study by Center for Educational and Instructional Technology Research team highlights connections between student perceptions of AI, academic integrity concerns and reported chatbot...

82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney diseaseZHUBEI CITY, Taiwan and RALEIGH, N.C.,...

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

MICHAEL FEINSTEIN CELEBRATES PRIDE MONTH WITH THE RELEASE OF NEW ANTHEM “GAYMEN” LEAD VOCALS BY motherfather, FEATURING A SPECIAL APPEARANCE BY LIZA MINNELLI

Michael Feinstein and Bobby Daye Unveil FeinDaye, a New Creative Venture Bridging Music, Entertainment and Live ExperiencesLOS ANGELES, June 5, 2026 /PRNewswire/ -- Acclaimed...

Greenberg Traurig Expands Health Care & FDA Capabilities in California with Addition of Deborah J. Rotenberg and Team

SACRAMENTO, Calif., June 5, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, LLP continues the growth of its Health Care & FDA Practice with the...

It Takes One Bank to Run a Normal IPO. SpaceX Hired 21. Here’s What That Tells You.

James Altucher's free presentation walks through what the unusually large underwriting group signals about the scale of the SpaceX listing.
James Altucher's free presentation walks through what the unusually large underwriting group signals about the scale of the SpaceX listing.

New Health Economic Evidence Shows Health & Cost Benefits When Starting Dialysis at Home

New UK economic analyses show improved patient outcomes and health system savings – including nearly £200 million in projected UK NHS savings over 5 years – through increased uptake of home-based peritoneal dialysis compared to in-center hemodialysis

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly...

“Go AI Native with MuleRun” Lights Up New York Tech Week

NEW YORK, June 4, 2026 /CNW/ -- As part of New York Tech Week, MuleRun successfully hosted "Go AI Native with MuleRun – Key...

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAuthor